The Latin America, Middle East and Africa Live Biotherapeutic Products And Microbiome CDMO Market would witness market growth of 50.9% CAGR during the forecast period (2023-2029).
The market is also developing as a result of the rising incidence of chronic diseases as well as the rising desire for personalized medication. These complicated medicines need to be developed and manufactured, and CDMOs with competence in these domains have the infrastructure and know-how to support such efforts. As a consequence, pharmaceutical and biotech businesses can delegate production to CDMOs, freeing up their resources for R&D.
In addition, there has been an increase in study on naturally occurring pharmaceuticals (LBPs) and the microbiota as possible therapeutic agents, which has led to an increase in research & development in these areas. This has increased the need for CDMOs with experience in these areas. The microbiome and its function in health and illness are now better understood because of developments in bioinformatics and sequencing technologies. This has made it possible to create microbiome-based medicines and more specialized, effective live biotherapeutic solutions.
According to the international diabetes federation (IDF), in 2021, 73 million persons (20-79) had diabetes in the Middle East and North Africa region. It is predicted that this number will rise to 136 million by 2045. Additionally, 27 million adult patients with diabetes are undiagnosed, accounting for 38% of the region's total adult patients with the disease. Impaired glucose tolerance (IGT), which puts people at higher risk of type 2 diabetes, affects 48 million adults in this region. In 2021, diabetes caused the death of approximately 796,000 individuals. As a result, there is a greater need for therapeutic interventions for the treatment of diseases like diabetes. Therefore, the presence of a significant patient base, along with improving healthcare infrastructure and disposable incomes, is driving the development of the market in the LAMEA region.
The Brazil market dominated the LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Country in 2022, thereby, achieving a market value of $1,486.2 Thousands by 2029. The Argentina market is experiencing a CAGR of 51.7% during (2023 - 2029). Additionally, The UAE market would exhibit a CAGR of 50.5% during (2023 - 2029).
Based on Application, the market is segmented into C.difficile, Crohns Disease, IBS, Diabetes, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Live Biotherapeutic Products And Microbiome CDMO Market is Projected to reach USD 159.1 Million by 2029, at a CAGR of 42.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB), Cerbios-Pharma SA, Biose Industrie, List Biological Laboratories, Inc., AcuraBio Pty Ltd (Ampersand Capital Partners), Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH), Quay Pharmaceuticals Ltd (SGS S.A.), BiomX, Inc., Lonza Group AG, and 4D Pharma Plc.
Scope of the Study
Market Segments Covered in the Report:
By Application
- C.difficile
- Crohns Disease
- IBS
- Diabetes
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
- Cerbios-Pharma SA
- Biose Industrie
- List Biological Laboratories, Inc.
- AcuraBio Pty Ltd (Ampersand Capital Partners)
- Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
- Quay Pharmaceuticals Ltd (SGS S.A.)
- BiomX, Inc.
- Lonza Group AG
- 4D Pharma Plc
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market, by Application
1.4.2 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application
3.1 LAMEA C.difficile Market by Country
3.2 LAMEA Crohns Disease Market by Country
3.3 LAMEA IBS Market by Country
3.4 LAMEA Diabetes Market by Country
3.5 LAMEA Others Market by Country
Chapter 4. LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Country
4.1 Brazil Live Biotherapeutic Products And Microbiome CDMO Market
4.1.1 Brazil Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.2 Argentina Live Biotherapeutic Products And Microbiome CDMO Market
4.2.1 Argentina Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.3 UAE Live Biotherapeutic Products And Microbiome CDMO Market
4.3.1 UAE Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.4 Saudi Arabia Live Biotherapeutic Products And Microbiome CDMO Market
4.4.1 Saudi Arabia Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.5 South Africa Live Biotherapeutic Products And Microbiome CDMO Market
4.5.1 South Africa Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.6 Nigeria Live Biotherapeutic Products And Microbiome CDMO Market
4.6.1 Nigeria Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.7 Rest of LAMEA Live Biotherapeutic Products And Microbiome CDMO Market
4.7.1 Rest of LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application
Chapter 5. Company Profiles
5.1 Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
5.1.1 Company Overview
5.1.2 Financial Analysis
5.1.3 Segmental and Regional Analysis
5.1.4 Recent strategies and developments:
5.1.4.1 Acquisition and Mergers:
5.1.4.2 Geographical Expansions:
5.2 Cerbios-Pharma SA
5.2.1 Company Overview
5.3 Biose Industrie
5.3.1 Company Overview
5.3.2 Recent strategies and developments:
5.3.2.1 Geographical Expansions:
5.4 List Biological Laboratories, Inc.
5.4.1 Company Overview
5.5 AcuraBio Pty Ltd (Ampersand Capital Partners)
5.5.1 Company Overview
5.6 Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
5.6.1 Company Overview
5.6.2 Financial Analysis
5.6.3 Segmental and Regional Analysis
5.6.4 Research & Development Expenses
5.7 Quay Pharmaceuticals Ltd (SGS S.A.)
5.7.1 Company Overview
5.7.2 Financial Analysis
5.7.3 Segmental Analysis
5.7.4 Recent strategies and developments:
5.7.4.1 Partnerships, Collaborations, and Agreements:
5.8 BiomX, Inc.
5.8.1 Company Overview
5.8.2 Research & Development Expenses
5.9 Lonza Group AG
5.9.1 Company Overview
5.9.2 Financial Analysis
5.9.3 Segmental and Regional Analysis
5.9.4 Research & Development Expenses
5.9.5 Recent strategies and developments:
5.9.5.1 Acquisition, Joint Ventures, and Mergers:
5.10. 4D Pharma Plc
5.10.1 Company Overview
5.10.2 Financial Analysis
5.10.3 Research & Development Expense
TABLE 1 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 2 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 3 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 4 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 5 LAMEA C.difficile Market by Country, 2019 - 2022, USD Thousands
TABLE 6 LAMEA C.difficile Market by Country, 2023 - 2029, USD Thousands
TABLE 7 LAMEA Crohns Disease Market by Country, 2019 - 2022, USD Thousands
TABLE 8 LAMEA Crohns Disease Market by Country, 2023 - 2029, USD Thousands
TABLE 9 LAMEA IBS Market by Country, 2019 - 2022, USD Thousands
TABLE 10 LAMEA IBS Market by Country, 2023 - 2029, USD Thousands
TABLE 11 LAMEA Diabetes Market by Country, 2019 - 2022, USD Thousands
TABLE 12 LAMEA Diabetes Market by Country, 2023 - 2029, USD Thousands
TABLE 13 LAMEA Others Market by Country, 2019 - 2022, USD Thousands
TABLE 14 LAMEA Others Market by Country, 2023 - 2029, USD Thousands
TABLE 15 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2019 - 2022, USD Thousands
TABLE 16 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2023 - 2029, USD Thousands
TABLE 17 Brazil Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 18 Brazil Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 19 Brazil Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 20 Brazil Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 21 Argentina Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 22 Argentina Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 23 Argentina Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 24 Argentina Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 25 UAE Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 26 UAE Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 27 UAE Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 28 UAE Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 29 Saudi Arabia Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 30 Saudi Arabia Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 31 Saudi Arabia Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 32 Saudi Arabia Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 33 South Africa Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 34 South Africa Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 35 South Africa Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 36 South Africa Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 37 Nigeria Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 38 Nigeria Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 39 Nigeria Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 40 Nigeria Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 41 Rest of LAMEA Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 42 Rest of LAMEA Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 43 Rest of LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 44 Rest of LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 45 Key Information – Arranta Bio Holdings, LLC
TABLE 46 Key Information – Cerbios-Pharma SA
TABLE 47 Key Information – Biose Industrie
TABLE 48 Key Information – List Biological Laboratories, Inc.
TABLE 49 Key Information – AcuraBio Pty Ltd
TABLE 50 Key Information – Wacker Chemie AG
TABLE 51 Key Information – Quay Pharmaceuticals Ltd
TABLE 52 Key Information – BiomX, Inc.
TABLE 53 Key Information – Lonza Group AG
TABLE 54 Key Information – 4D Pharma Plc
List of Figures
FIG 1 Methodology for the research
FIG 2 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market share by Application, 2022
FIG 3 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market share by Application, 2029
FIG 4 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2029, USD Thousands
FIG 5 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market share by Country, 2022
FIG 6 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market share by Country, 2029
FIG 7 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2019 - 2029, USD Thousands